top of page
Advancing Towards Breakthrough Outcomes for Cancer & Autoimmune Patients
NAYA Therapeutics is focused on the clinical development and strategic acquisition of first and best-in-class clinical-stage therapeutics for the treatment of cancer and autoimmune diseases.


We leverage the impact of new drug modalities, novel targets, and AI-powered translational medicine to achieve breakthrough outcomes for patients.


NAYA Therapeutics has 2 development franchises: Solid Tumors & Immunotherapy. 

Our Solid Tumors franchise is advancing two novel therapeutics for the treatment of hepatocellular carcinoma (HCC):
NY-303: GPC3 x NKp46 FLEX-NK™ Bifunctional Antibody
NY-500: PD1 x VEGF FLEX Bifunctional Antibody
Our Immunotherapy franchise is advancing a novel therapeutic for the treatment of both multiple myeloma & autoimmune diseases:
NY-338: CD38 x NKp46 FLEX-NK™ Bifunctional Antibody
Data for NY-303 & NY-338 has been presented at major oncology meetings including ASH, AACR, SITC, ESMO, and ASGCT.
Clinical development has been designed by our scientific advisory board of leading liver cancer, multiple myeloma, and autoimmune disease experts to allow for early inflection points and accelerated development based on early data.
bottom of page